Answers are grounded in this paper and cite their sources.
GCA and PMR may be associated with COVID-19 vaccines, although risk appears lower than with influenza vaccines. Dear Editor, COVID-19 vaccines rely on next-generation vaccine platforms of which safety profiles are, to date, not well characterized. Sporadic cases of GCA secondary to COVID-19 vaccination have been recently reported to the French Pharmacovigilance Network. However, vaccine causality is currently not assessed. Hence, we aimed to describe cases of GCA and PMR following COVID-19 vaccination using a global pharmacovigilance database, and assess a potential safety signal. Of the 26 246 383 reports in VigiBase until 30 June, 2021, 1 295 482 reports concerned COVID-19 vaccines, among which we observed 147 GCA cases, 290 PMR cases and 9 GCA with PMR cases (Table 1). Of the 446 patients, 260 were female (58.3%), and the median (interquartile range [IQR]) age was 71.5 (64–78) years. Median (IQR) time from vaccination to first symptoms onset was 4 (1–14) days. Cases reported with mRNA vaccine were 61.9% of the total and with viral vector vaccine 37.4%. Seriousness, as fatal cases, life-threatening condition, requiring hospitalization, resulting in significant disability/incapacity, and other medically important conditions, was reported in 277 cases (62.1%). Among 317 687 reports concerning influenza vaccines, there were 78, 303 and 14 cases of GCA, PMR and GCA with PMR, respectively. COVID-19 vaccines were associated with an increased reporting in GCA (ROR 2.7, 95% CI: 2.3, 3.2) and PMR (ROR 2.3, 95% CI: 2.0, 2.6). These results were consistent with further sensitivity analyses and subgroup analysis by vaccine type (Table 1). However, when compared with the use of influenza vaccines, we did not find an increased reporting of GCA (ROR 0.5, 95% CI: 0.4, 0.7) or PMR cases (ROR 0.2, 95% CI: 0.2, 0.2). These results were consistent with further sensitivity analyses restricted to serious reports and to reports originating from a healthcare provider. Similar findings were retrieved after adjustment for patient age. Characteristics of giant cell arteritis and polymyalgia rheumatica cases reported with COVID-19 vaccines in the WHO pharmacovigilance database Time from the first available vaccine shot date to onset of symptoms reported. Other suspected drugs reported in cases were prednisone (one case), prednisolone (one case), tick-borne encephalitis vaccine and pneumococcal vaccine polysaccharide 23-valent (one case). According MedDRA preferred terms. Cases with fatal or life-threatening outcome, requiring hospitalization, resulting in significant disability/incapacity, or any other medically important conditions. IQR: interquartile range; N: number of non-cases, i.e. all other adverse drug reactions reports; ROR: reporting odds ratio. Characteristics of giant cell arteritis and polymyalgia rheumatica cases reported with COVID-19 vaccines in the WHO pharmacovigilance database Time from the first available vaccine shot date to onset of symptoms reported. Other suspected drugs reported in cases were prednisone (one case), prednisolone (one case), tick-borne encephalitis vaccine and pneumococcal vaccine polysaccharide 23-valent (one case). According MedDRA preferred terms. Cases with fatal or life-threatening outcome, requiring hospitalization, resulting in significant disability/incapacity, or any other medically important conditions. IQR: interquartile range; N: number of non-cases, i.e. all other adverse drug reactions reports; ROR: reporting odds ratio. Our study first describes the GCA and PMR cases after COVID-19 vaccination at a global level and identifies a potential safety signal. First symptoms occurred during the next few days after the vaccine shot, shorter than that observed following influenza vaccination [3]. Similarly, new onset or flare of autoimmune diseases with a short latency after the first mRNA vaccine shot has been described [4, 5]. GCA and PMR pathophysiology are not fully understood but environmental factors and infections are likely to play a role [6]. GCA and PMR cases have been previously reported after influenza vaccination, which could act as an inflammatory trigger [3]. Hence, vaccination may reveal first symptoms of a possible underlying disease. However, our findings suggest a reduced relative risk of GCA or PMR following COVID-19 vaccination, compared with influenza vaccination. Our study has some intrinsic limitations, related to the pharmacovigilance database, including under-reporting and heterogeneous causality assessment among reports. To limit information bias and selective reporting, we compared reporting following COVID-19 vaccines with that associated with the use of influenza vaccines. Indeed, in the first months of the current mass immunization campaign, target populations were similar to the seasonal influenza immunization campaign. However, our findings may be underestimated as study groups could be imbalanced due to the high number of reactogenicity-related reports for COVID-19 vaccine. Finally, although data based on spontaneous reports cannot accurately quantify the risk, our approach has proven interest for signal detection [1]. Overall, our study supports a potential safety signal for GCA and PMR with COVID-19 vaccines. Further data are needed to confirm this signal. Nevertheless, COVID-19 vaccine benefits dramatically outweigh this potential risk, which appears very rare relative to the billions of doses administered so far. The authors would like to thank all the healthcare workers and the French Pharmacovigilance Network involved in the large immunization campaign and in its safety monitoring, especially the experts for the French National Medicine Agency (ANSM): Dr Marina Atzenhoffer, Dr Sophie Gautier, Dr Valérie Gras-Champel, Dr Marion Lepelley, Dr Nathalie Massy, Dr Joelle Micallef, Dr Antoine Pariente, Dr Francesco Salvo, Dr Marie-Blanche Valnet-Rabier. A.-P.J.-B., A.G., J.-M.T. and L.C. are members of the French Pharmacovigilance Network. Concept and design: C.M., L.C., B.T. Acquisition, analysis or interpretation of data: C.M., L.C., B.T. Drafting of the manuscript: C.M., B.T., L.C. Critical review of the manuscripts: A.-P.J.-B., A.G., J.-M.T. Statistical analysis: C.M. Administrative, technical, or material support: L.C. Supervision: L.C., B.T. Funding: No specific funding was received from any bodies in the public, commercial or not-for-profit sectors to carry out the work described in this article. Disclosure statement: B.
No takes yet. Share an insight, caveat, or question.
Mettler et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: